TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.80 USD
-0.12 (-4.16%)
Updated Apr 29, 2024 02:08 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TFFP 2.80 -0.12(-4.16%)
Will TFFP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TFFP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TFFP
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
TFFP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
Other News for TFFP
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
TFF Pharmaceuticals Signals Advancements in Investor Update
TFF Pharmaceuticals files to sell 147,500 shares of common stock for holders
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals announces data from TFF TAC Phase 2 trial